Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:44 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine
NCT02246075 · FORUM Pharmaceuticals Inc · PHASE2 · withdrawn · last registry update 2015-10-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Forum has decided not to proceed with this study at this time.” | – | Registry record, FORUM Pharmaceuticals Inc |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CHRNA7 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-06-16Also stopped (terminated): University of Colorado, Denver, DMXB-A 150 mg + DMXB-A 75 mg (NCT02111551)
- 2016-04-19Also stopped (terminated): Novartis Pharmaceuticals, AQW051 + Placebo (NCT00582855)
- 2016-02-05Results posted on the registry: VA Office of Research and Development, Pharmacokinetic (NCT00952393)
- 2015-02-10Also stopped (terminated): Asmacure Ltée, ASM-024 (NCT01793298)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision